{"abstract":"The National Institute of Child Health and Human Development, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and foreign Patents and Patent Applications listed in the Supplementary Information section of this notice to SubRed Pty Ltd located in Australia, registered in Victoria.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/04/09/2021-07316.html","cfr_references":[],"citation":"86 FR 18545","comment_url":null,"comments_close_on":"2021-04-26","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Child Health and Human Development c/o National Cancer Institute's Technology Transfer Center on or before April 26, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-07316","effective_on":null,"end_page":18546,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/04/09/2021-07316.xml","html_url":"https://www.federalregister.gov/documents/2021/04/09/2021-07316/prospective-grant-of-an-exclusive-patent-license-n-butyldeoxynojirimycin-to-treat-smith-lemli-opitz","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-07316?publication_date=2021-04-09","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-04-09/2021-07316/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":97,"last_updated":"2026-08-26 18:15:08 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-04-09/pdf/2021-07316.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-07316.pdf?1617885931","publication_date":"2021-04-09","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/04/09/2021-07316.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:32:09Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":18545,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype","toc_doc":"N-butyldeoxynojirimycin to Treat Smith-Lemli Opitz Syndrome and Diseases that Exhibit a Similar NPC-like Cellular Phenotype","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}